CIK 0001788028 · <br>Emerging growth company
Jasper Therapeutics, Inc.
Sign in to watch- Ticker
- JSPR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 842984849
- Phone
- 6505491400
- Business address
- 2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA, 94065
- Former names
- Amplitude Healthcare Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-15 | CROSS HERB Chief Financial Officer | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2024-02-15 | Tucker Edwin Jonathan Chief Medical Officer | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2024-02-08 | Carlyle Group Inc. Former 10% Owner | Purchase | +190,000 | $12.95 | $2.5M | 1,066,189 |
| 2024-02-08 | Velan Capital Investment Management LP 10% owner | Purchase | +350,000 | $12.95 | $4.5M | 1,188,500 |
| 2023-11-28 | WIGGANS THOMAS G Director | Purchase | +10,000 | $0.65 | $6K | 50,000 |
| 2023-11-21 | WIGGANS THOMAS G Director | Purchase | +10,000 | $0.64 | $6K | 40,000 |
| 2023-11-20 | WIGGANS THOMAS G Director | Purchase | +10,000 | $0.63 | $6K | 30,000 |
| 2023-11-17 | WIGGANS THOMAS G Director | Purchase | +10,000 | $0.60 | $6K | 20,000 |
| 2023-11-16 | WIGGANS THOMAS G Director | Purchase | +10,000 | $0.60 | $6K | 10,000 |
| 2023-11-01 | WIGGANS THOMAS G Director | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2023-10-13 | Lis William Director | Sale 10b5-1 | −7,965 | $0.85 | $7K | 53,521 |
| 2023-10-12 | Mahal Jeetinder Singh Chief Operating Officer | Shares withheld for taxes | −37,126 | $0.85 | $32K | 250,097 |
| 2023-10-12 | MARTELL RON President, CEO & Director | Shares withheld for taxes | −87,531 | $0.85 | $74K | 331,188 |
| 2023-09-22 | CROSS HERB Chief Financial Officer | Grant or award · Stock Option (right to buy) | +550,000 | 550,000 | ||
| 2023-06-20 | Brun Scott C. Director | Grant or award · Stock Option (right to buy) | +94,000 | 94,000 | ||
| 2023-06-13 | Mahal Jeetinder Singh See Remarks | Option exercise 10b5-1 | +9,000 | $0.71 | $6K | 296,223 |
| 2023-06-13 | Mahal Jeetinder Singh See Remarks | Sale 10b5-1 | −9,000 | $1.66 | $15K | 287,223 |
| 2023-06-13 | Mahal Jeetinder Singh See Remarks | Option exercise · Stock Option (right to buy) 10b5-1 | +9,000 | 173,713 | ||
| 2023-06-12 | Tucker Edwin Jonathan Chief Medical Officer | Grant or award · Stock Option (right to buy) | +400,000 | 400,000 | ||
| 2023-06-07 | Kapoor Vishal Director | Grant or award · Stock Option (right to buy) | +47,000 | 47,000 |
Page 4 of 7 · 129 trades